Business Wire

Introducing Lasso: A New Food Tech Company Redefining Consumer Packaged Foods

14.10.2025 19:34:00 CEST | Business Wire | Press release

Share

Backed by $6.5M in new funding, Lasso is filling a void in the food industry with its proprietary fiber spinning technology that transforms simple ingredients into clean-label, protein-packed foods.

Lasso today announced its official launch and the introduction of its proprietary technology, Lasso SpinTech. This breakthrough system upends the outdated standards of ultra-processed foods using physics to weave together protein and fiber to make previously unattainable new consumer products. With a new $6.5M raise, Lasso is bringing its technology to the world by launching its own brands and licensing to global partners to create a new generation of healthier foods.

Guided by CEO Mike Messersmith, the Lasso team spent the past year deploying its commercial-scale technology to create innovative clean-label products including protein-packed snacks and pet food—expanding beyond its first plant-based meat application under the Tender Food brand. Lasso’s latest $6.5M in capital, led by Rhapsody Venture Partners with participation from Safar Partners, Claridge Venture Partners, and others, will enable the company to commercialize its transformative technology across new high growth food categories.

“Consumers are no longer accepting the status quo in packaged food. Evidence of that is everywhere from the MAHA movement to vocal pushbacks on ultra-processed foods, and the influence of GLP-1 therapies on consumption patterns and preferences,” said Messersmith. “The industry is desperate for new, innovative solutions, but has been handicapped by antiquated processing machines invented over 100 years ago–and wholly ill-equipped to meet the needs of consumers in 2025. At Lasso, we want to use our technology to step into that void and create progress. Our patented technology offers new ways of creating protein and fiber-rich foods with clean labels and competitive cost structures that will jumpstart major momentum in growing categories across the grocery store.”

Lasso originated at Harvard University’s Wyss Institute, where founders Kit Parker, Luke MacQueen, Christophe Chantre, and Grant Gonzalez invented and spent seven years refining a novel food-processing technology – an “advanced cotton candy machine” capable of creating delicious, nutritious foods with exceptional texture and cost efficiency from nearly any ingredient. Their work culminated in the 2020 launch of Tender Food, which applied Lasso SpinTech to create category-leading plant-based meat. Tender Food will remain a brand under Lasso’s broader portfolio, soon to be joined by several to-be-announced new brands, all built on Lasso SpinTech.

Lasso SpinTech has come a long way since then — scaling from a countertop system in a lab to a commercial-scale system producing hundreds of thousands of pounds of product annually without the need for high heat, excess sugars or artificial additives. Today, the system is compact (about the size of a washing machine) and ultra-efficient (using less energy than a toaster oven) - a fraction of the capital and operating cost of competitive technologies. With nearly limitless ingredient combinations and texture flexibility, Lasso’s technology has the potential to create an endless range of craveable food products.

Messersmith closed: “This fundraise marks a major milestone for Lasso. We are on the cusp of introducing truly innovative new foods made of simple ingredients that everyone understands - both through brands we create and in working with global partners to bring new products to market through licensing agreements. There is nothing on the market that can match what Lasso can achieve with this technology. We are thrilled for people to taste these new products and take this business to a whole new level.”

About Lasso

Lasso is transforming our food system with a breakthrough technology that converts simple ingredients into premium food products. Developed by Harvard scientists at the Wyss Institute, Lasso’s innovative technology “spins” fibers, leveraging centrifugal force to restructure simple ingredients into nutritionally advantaged, affordable food products. With 1,000+ ingredient combinations and vast parameters to control fiber thickness, composition, arrangement, density, and moisture content, Lasso gives food producers the adaptability to navigate shifting supply chains, evolving consumer preferences, and global food trends - setting a new standard for the future of food production. Learn more at www.lassolabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014740080/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye

Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse

Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk

Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release

For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye